1. General Information
The new Alzheimer’s disease drug invention relates to the intranasal administration of a formulation comprising of an effective amount of curcumin to the olfactory mucosa across the cribriform plate and into the brain. This improves curcumin brain bioavailability by administering curcumin via the nasal route in order to deliver it through the olfactory mucosa and to the brain, and reduces the dose required for its beneficial effect. This mode of delivery will also pass less curcumin into the blood circulation, hence result in lower plasma concentrations of metabolites of curcumin, therefore fewer side effects and the drug will be more tolerable and effective. The new drug also poses therapeutic advantages for brain stroke and multiple sclerosis. Besides these beneficial effects of curcumin, the new drug overcomes the bioavailability problems associated with the oral delivery of curcumin such as headache, rash and diarrhea.
Research has reported that curcumin inhibits the in vitro formation of amyloid beta oligomers, and blocks the in vitro toxicity of Aβ 1-42 oligomers in differentiated neuroblastoma cells. In addition to its beneficial action against soluble beta amyloid, curcumin has considerable anti-oxidative properties and also inhibits the expression of pro-inflammatory cytokines. Further curcumin is able to effectively act against many targets of AD. Curcumin is currently the subject of an FDA approved IND clinical trial at the UCLA Alzheimer Center in the treatment of mild to moderate AD patients.
This primary research initiative is being conducted to gain deeper insight in curcumin prodrugs for Alzheimer’s disease. The research aims to understand the doctors opinion about existing Alzheimer’s disease treatments and in light of the new drugs advantages estimate the market potential for the new drug. In this context your response to the following survey will be highly valuable in conducting a feasibility analysis for the new drug. We thank you for your time and effort.